This improved antigen presentation increases the efficaciousness of immune checkpoint inhibitors, like PD-L1/PD-1 inhibitors, by improving their capacity to identify and target tumor cells, leading to a more potent anti-tumor immune response [22]. This evidence concerns the gene CD274 and neoplasm.